Single Dose Mass Balance Study With [14C]Iruplinalkib (WX-0593) In Healthy Male Volunteers

Summary

This is an open-label, single dose, mass balance and biotransformation study conducted at 1 study center in China. This study will evaluate the absorption, distribution, metabolism, and elimination (ADME), mass balance, safety, and tolerability of a single dose of intravenously administered \[14C\]Iruplinalkib (WX-0593) in Chinese healthy male volunteers.

Timeline

Start

2020-04-15

Primary completion

2020-12-15

Completion

2021-01-13

Drugs

Indications

No indication recorded.